title: Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
abstract: We have designed an amphiphilic prodrug of the anticancer agent gemcitabine (dFdC), by covalent coupling to squalene. This bioconjugate, which self-assembled into nanoparticles (NPs) in water, was previously found to display an impressive anticancer activity both in vitro and in vivo. The present study aims to investigate the impact of SQdFdC nanoparticles on cellular membranes. MTT assays showed that, in the nanomolar range, squalenoyl gemcitabine (SQdFdC) was slightly less active than dFdC on a panel of human cancer cell lines, in vitro. However, above 10 μmol L(-1) SQdFdC was considerably more cytotoxic than dFdC. Contrarily to its parent drug, SQdFdC also induced cell lysis in a few hours, as evidenced by LDH release assays. Erythrocytes were used as an experimental model insensitive to the antimetabolic activity of dFdC to further investigate the putative membrane-related cytotoxic activity of SQdFdC. The bioconjugate also induced hemolysis in a time- and dose-dependent fashion, unlike squalene or dFdC, which clearly proved that SQdFdC could permeabilize cellular membranes. Structural X-ray diffraction and calorimetry studies were conducted in order to elucidate the mechanism accounting for these observations. They confirmed that SQdFdC could be transferred from NPs to phospholipid bilayers and that the insertion of the prodrug within model membranes resulted in the formation of nonlamellar structures, which are known to promote membrane leakage. As a whole, our results suggested that due to its amphiphilic nature, the cell uptake of SQdFdC resulted in its insertion into cellular membranes, which could lead to the formation of nonlamellar structures and to membrane permeation. Whether this mechanism could be the source of toxicity in vivo, however, remains to be established, since preclinical studies have clearly proven that squalenoyl gemcitabine displayed a good toxicity profile.
authors.affiliation: Univ. Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie, Châtenay-Malabry, France. lucien.bildstein@gmail.com
authors.forename: L
authors.initials: L
authors.lastname: Bildstein
authors.forename: B
authors.initials: B
authors.lastname: Pili
authors.forename: V
authors.initials: V
authors.lastname: Marsaud
authors.forename: S
authors.initials: S
authors.lastname: Wack
authors.forename: F
authors.initials: F
authors.lastname: Meneau
authors.forename: S
authors.initials: S
authors.lastname: Lepêtre-Mouelhi
authors.forename: D
authors.initials: D
authors.lastname: Desmaële
authors.forename: C
authors.initials: C
authors.lastname: Bourgaux
authors.forename: P
authors.initials: P
authors.lastname: Couvreur
authors.forename: C
authors.initials: C
authors.lastname: Dubernet
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D002152:Calorimetry, Differential Scanning; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D051379:Mice; D008815:Mice, Inbred Strains; D010743:Phospholipids / Q000737:chemistry; D011355:Prodrugs / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D013185:Squalene / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D013501:Surface-Active Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D014961:X-Ray Diffraction
chemical_list: C525919:4-(N)-tris-nor-qualenoyl-gemcitabine; D000964:Antimetabolites, Antineoplastic; D010743:Phospholipids; D011355:Prodrugs; D013501:Surface-Active Agents; D003841:Deoxycytidine; D013185:Squalene